Skip to main content
SpringerLink
Log in
Book cover

Alzheimer’s Disease pp 193–202Cite as

Galantamine in Treatment of AD

  • Chapter

  • 356 Accesses

Part of the book series: Current Clinical Neurology ((CCNEU))

Abstract

The cholinergic hypothesis proposes that well-defined deficits in cholinergic neurotransmission contribute to cognitive dysfunction in Alzheimer’s disease (AD), and that enhancing cholinergic transmission will lead to improved outcome (1). Several acetylcholinesterase inhibitors (AChEI) have been approved during the past few years on the basis of clinical trials, demonstrating that these agents improve or maintain cognitive function in patients with possible AD. Thus far all AChEI have been shown to be efficacious as a class and are considered a mainstay of AD treatment. Galantamine is the newest member of this class of agents at present.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bartus, R.T. et al.: The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408–414.

    Article  PubMed  CAS  Google Scholar 

  2. Levin, E.D.; Simon, B.B.: Nicotinic acetylcholine involvement in cognitive functions in animals. Psychopharmacology 1998; 138: 217–230.

    Article  PubMed  CAS  Google Scholar 

  3. Whitehouse, P.J. et al.: Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science 1982; 215: 1237–1239.

    Article  PubMed  CAS  Google Scholar 

  4. Schroeder, H. et al.: Nicotinic cholinoreceptive neurons of the frontal cortex are reduced in Alzheimer’s disease. Neurobiol Aging 1991; 12: 259–262.

    Article  Google Scholar 

  5. Nordberg, A.; Lundqvist, H.; Hartvig, P.: Kinetic analysis of regional (S) (-) 11C- nicotinic binding in normal and Alzheimer brains in vivo assessment using positron emission tomography. Alzheimer’s Dis Assoc Disord 1995; 9: 21–27.

    Article  CAS  Google Scholar 

  6. Perry, E. et al.: Alteration in nicotinic binding sites in Parkinson’s disease, Lewy body dementia and Alzheimer’s disease: possible index of early neuropathology. Neuroscience 1995; 64: 385–395.

    Article  PubMed  CAS  Google Scholar 

  7. Decker, M.W.: Animal models of cognitive functions. Crit Rev Neurobiol 1995; 9: 321–343.

    PubMed  CAS  Google Scholar 

  8. Levin, E.D.; Rezvani, A.H.: Development of nicotinic drug therapy for cognitive disorders. Eur J Pharmacol 2000; 393: 141–146.

    Article  PubMed  CAS  Google Scholar 

  9. Parks, R.W. et al.: Increased regional cerebral glucose metabolism and semantic memory performance in Alzheimer’s disease: a pilot double-blind transdermal nicotine positron emission tomography study. Neuropsychol Rev 1996; 6: 61–79.

    Article  PubMed  CAS  Google Scholar 

  10. Maelicke, A.; Albuquerque, E.X.: Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer’s disease. Eur J Pharmacol 2000; 393: 165–170.

    Article  PubMed  CAS  Google Scholar 

  11. Inestrosa, N.C. et al.: Acetylcholinesterases accelerate assembly of amyloid B-peptides into Alzheimer’s fibrils: possible role of the peripheral site of the enzyme. Neuron 1996; 16: 881–889.

    Article  PubMed  CAS  Google Scholar 

  12. Williams, M.; Arneric, S.P.: Alzheimer’s disease: prospects for treatment in the next decade. In: Brioni, J.D.; Decker, M.W. (eds.): Pharmacological treatment of Alzheimer’s disease. Wiley-Liss, New York, 1997: 525–542.

    Google Scholar 

  13. Meyer, E.M. et al.: Cytoprotective actions of nicotinic receptor stimulation (abst). Fifth Int Conf Alzheimer’s Disease and Related Disorders, Osaka, Japan, 1996.

    Google Scholar 

  14. Lopez, O.L. et al.: Cholinesterase inhibitor treatment alters the natural history of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2002; 72: 310–314.

    Article  PubMed  CAS  Google Scholar 

  15. Rosen, W.G.; Mohs, R.C.; Davis, K.L.: A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984; 141: 1356–1364.

    PubMed  CAS  Google Scholar 

  16. Torfs, K.; Feldman, H., on behalf of the Sabeluzole Study Groups. 12-month decline in cognitive and daily function in patients with mild to-moderate Alzheimer’s disease: two randomized, placebo-controlled studies (poster). World Alzheimer Congress, Washington, DC, July 9–13, 2000.

    Google Scholar 

  17. Bartus, R.T.: On neurodegenerative diseases, models and treatment strategies, lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 2000; 163: 495–529.

    Article  PubMed  CAS  Google Scholar 

  18. Cummings, J.L.; Kaufer, D.: Neuropsychiatric aspects of Alzheimer’s disease: the cholinergic hypothesis revisited. Neurology 1996; 47: 876–883.

    Article  PubMed  CAS  Google Scholar 

  19. Tariot, P.N. et al.: A 5-month, randomized placebo-controlled trial of galantamine in Alzheimer’s disease. Neurology 2000; 54: 2269–2276.

    Article  PubMed  CAS  Google Scholar 

  20. Raskind, M.A. et al. and the Galantamine USA-1 Study Group: Galantamine in AD: a 6-month randomized placebo-controlled trial with a 6-month extension. Neurology 2000; 54: 2261–2268.

    Article  PubMed  CAS  Google Scholar 

  21. Wilcock, G.K.; Lilienfeld, S.; Gaens, E. on behalf of the Galantamine International-1 Study Group. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicenter randomized controlled trial. Br Med J 2000; 321: 1445–1449.

    Google Scholar 

  22. Wilkinson, D.; Murray, J.: Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 2001; 16: 852–857.

    Article  PubMed  CAS  Google Scholar 

  23. Rockwood, K. et al.: Effects of flexible galantamine dose in Alzheimer’s disease: a randomized, controlled trial. J Neurol Neurosurg Psychiatry 2001; 71: 589–595.

    Article  PubMed  CAS  Google Scholar 

  24. Raskind, M.A.; Peskind, E.; Truyen, L.: Galantamine provides long-term cognitive benefits for at least 36 months in patients with Alzheimer’s disease (poster). American Psychiatric Association 155th Annual Meeting, Philadelphia, May 18–23, 2002.

    Google Scholar 

  25. Farlow, M.R. et al.: Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer’s disease. Neurology 1998; 50: 669–677.

    Article  PubMed  CAS  Google Scholar 

  26. Erkinjutti, T. et al: Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomized trial. Lancet 2002; 1359: 1283–1290.

    Article  Google Scholar 

  27. Small, G.W.; Lilenfield, S.: Galantamine demonstrates sustained cognitive benefits in patients with Alzheimer’s disease, vascular dementia, or Alzheimer’s disease with cerebrovascular disease (poster). American Psychiatric Association 155th Annual Meeting, Philadelphia, May 18–23, 2002.

    Google Scholar 

  28. Leber, P.: Guidelines for the clinical evaluation of anti-dementia drugs, 1st draft. U.S. Food and Drug Administration, Rockville, MD, 1990.

    Google Scholar 

  29. Feldman, H. et al.: The disability assessment for dementia scale: a 12-month study of functional ability in mild to moderate severity Alzheimer’ disease. Alzheimer’s Dis Assoc Disord 2001; 15: 89–95.

    Article  CAS  Google Scholar 

  30. Mintzer, J.E.; Faison, W.E.: Prolonged benefits with acetylcholinesterase inhibitors are exhibited in patients with Alzheimer’s disease (poster). American Association for Geriatric Psychiatry 15th Annual Meeting, Orlando, Fla, February 24–27, 2002.

    Google Scholar 

  31. Tariot, P.N.; Blazina, L.: The psychopathology of dementia. In: Morris, J. (ed.): Handbook of dementing illnesses. Marcel Decker, New York, 1993: 461–475.

    Google Scholar 

  32. Burke, E.; Lilienfeld, S.: Galantamine improves behavior and reduces caregiver distress in patients with Alzheimer’s disease, vascular dementia, or Alzheimer’s disease with cerebrovacular disease (poster). American Psychiatric Association 155th Annual Meeting, Philadelphia, May 18–23, 2002.

    Google Scholar 

  33. Tariot, P.N.: Treating non-cognitive problems: other classes of psychotropics in dementia. In: Qizilbash, N.; et al. (eds.): Evidence-based practice of dementia. Blackwell, Oxford, UK, 2002: 671–694.

    Google Scholar 

  34. Feldman, H. et al.: A 24-week randomized, double blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001; 57: 613–620.

    Article  PubMed  CAS  Google Scholar 

  35. Wilcock, G.; Lilienfeld, S.: Galantamine alleviates caregiver burden in Alzheimer’s disease: a 6- month-placebo-controlled study (poster). World Alzheimer’s Congress, Washington, DC, July 9–18, 2000.

    Google Scholar 

  36. Lilenfeld, S.; Gaens, E.: Galantamine alleviates caregiver burden in Alzheimer’s disease: a 12-month study (poster). 5th Congress European Federation of Neurological Studies, Copenhagen, October 14–18, 2000.

    Google Scholar 

  37. Getsios, D. et al.: The AHEAD Study Group. Assessment of Health Economics in Alzheimer’s Disease (AHEAD): galantamine treatment in Canada. Neurology 2002; 57: 972–978.

    Article  Google Scholar 

  38. Ernst, R.L. et al.: Cognitive function and cost of Alzheimer disease. Arch Neurol 1997; 54: 687–693.

    Article  PubMed  CAS  Google Scholar 

  39. Knopman, D. et al.: Long term tacrine treatment: effects on nursing home placement and mortality: tacrine study group. Neurology 1996; 47: 166–177.

    Article  PubMed  CAS  Google Scholar 

  40. Kaye, J.; Schneider, L.S.; Qizilbash, N.: Therapies for cognitive symptoms, disease modification and prevention. In: Qizilbash, N.; et al. (eds.): Evidence-based practice of dementia. Blackwell, Oxford, UK, 2002: 461–588.

    Google Scholar 

  41. Qizilbash, N.; Schneider, L.S.: Summary, practical recommendations and opinion on therapies for cognitive symptoms, disease modification and prevention. In: Qizilbash, N.; et al. (eds.): Evidence-based practice of dementia. Blackwell, Oxford, UK, 2002: 560–588.

    Google Scholar 

Download references

Authors
  1. M. Saleem Ismail
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pierre N. Tariot
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The University of Oklahoma College of Medicine, USA

    Ralph W. Richter MD, FACP (Clinical Professor of Neurology and Psychiatry, Director) (Clinical Professor of Neurology and Psychiatry, Director)

  2. Alzheimer’s Disease Research Unit, St. John Medical Center, Tulsa, OK, USA

    Ralph W. Richter MD, FACP (Clinical Professor of Neurology and Psychiatry, Director) (Clinical Professor of Neurology and Psychiatry, Director)

  3. Tulsa, OK, USA

    Brigitte Zoeller Richter DiplPharm (Pharmacist, Publicist) (Pharmacist, Publicist)

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Ismail, M.S., Tariot, P.N. (2004). Galantamine in Treatment of AD. In: Richter, R.W., Richter, B.Z. (eds) Alzheimer’s Disease. Current Clinical Neurology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-661-4_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-661-4_22

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-4485-9

  • Online ISBN: 978-1-59259-661-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation